11 results about "A antigen" patented technology

This invention discloses a method for preparing A, B, and Lewis blood group antigens, wherein the A, B, and Lewis blood group antigens are specifically blood group A. tri Antigen, B tri Antigen, Le a Antigen and Le b Antigen. A one-pot photosensitive method was used to achieve blood group A. tri Antigen, B tri Antigen, Le a Antigen and Le b The method for obtaining large quantities of antigens, as described in this invention, features mild reaction conditions, shortened purification steps, simplicity, high efficiency, environmental friendliness, low cost, and high yield and purity of the target substance. This invention provides a practical and rapid chemical synthesis route for blood type A antigens. tri Antigen, B tri Antigen, Le a Antigen and Le b Antigens provide tools for the development of norovirus vaccines and related antibodies, and therefore have great application prospects.

The present invention provides a chimeric antigen receptor (CAR) system comprising; (i) a receptor component comprising a antigen binding domain and a first binding domain; and (ii) a signalling component comprising a signalling domain and a second binding domain which binds the single domain binder of the first binding domain of the receptor component wherein either the first or second binding domains comprise a single domain binder, and wherein, binding of the first and second binding domains is disrupted by the presence of an agent, such that in the absence of the agent, the receptor component and the signalling component heterodimerize and binding of the antigen binding domain to antigen results in signalling through the signalling domain; whereas in the presence of the agent, the receptor component and the signalling component do not heterodimerize and binding of the antigen binding domain to antigen does not result in signalling through the signalling domain.

1. The material of the article to which this design relates is synthetic resin. 2. The article to which this design relates is a set of teaching tools that can be used to learn about ABO blood types and RhD blood types. 3. Teaching tool A represents red blood cells, teaching tool B represents type A antigens, teaching tool C represents type B antigens, teaching tool D represents RhD antigens, teaching tool E represents anti-type A antibodies, teaching tool F represents anti-type B antibodies, and teaching tool G represents anti-RhD antibodies. 4. The article to which this design relates is designed to easily explain the phenomenon of red blood cells and the antigens present on their surfaces reacting with antibodies in serum. 5. Reference Figures 1 to 3 show the product in use. Reference Figure 1 shows that when type B red blood cells are reacted with a type A person, the anti-B antibodies in the type A serum and the type B red blood cells agglutinate. Reference Figure 2 shows that when type A red blood cells are reacted with a type B person, the anti-A antibodies in the type B serum and the type A red blood cells agglutinate. Reference Figure 3 shows the RhD phenomenon, where red blood cells with RhD antigens on their surface agglutinate with anti-RhD antibodies.

This invention relates to the field of biological detection, and in particular to an IgM antibody for preventing erythrocyte agglutination, its preparation method, and its uses. The IgM antibody for preventing erythrocyte agglutination is obtained by mixing and incubating a natural IgM antibody with DTT. The IgM antibody can be used to prepare products for detecting ABO blood types and products for detecting the expression levels of type A antigen and / or type B antigen. The prepared products can be used for quantitative detection of ABO antigen expression, studying changes in ABO antigen expression levels among different genotypes, and studying diseases related to ABO antigen expression levels.

The invention discloses gene modification carrying an immunological enhancement element and application of the gene modification, and relates to the technical field of biological medicine and gene engineering. B, at least one coding nucleic acid sequence IE of an immunological enhancement element, wherein the immunological enhancement element is used for enhancing antigen presentation, immunological co-stimulation signal transmission or positive regulation of a local immune microenvironment; c, at least one of a signal peptide segment SP and a membrane anchoring localization domain TM; the d expression regulation unit comprises a promoter Pr for driving the expression of Ag and IE and a transcription termination signal pA; the e-site strategy related sequence organization comprises a homologous segment left side HS-L and a homologous segment right side HS-R; wherein the Ag and the IE are assembled in the same expression framework, the IE is located at one of the upstream and the downstream of the Ag, antigen presentation and costimulatory signals are synchronous and stable, the immune response intensity and durability are improved, and inter-individual and inter-batch fluctuation is reduced.

The application belongs to the technical field of immunology, and particularly relates to a sheep scavenger receptor A antigen polypeptide, a polyclonal antibody thereof, a preparation method and application, and an amino acid sequence of the sheep SRA antigen polypeptide is KSLDEKQVHLEQELKG. A rabbit SRA polyclonal antibody is prepared by using the antigen polypeptide, the rabbit SRA polyclonal antibody has good reactivity and specificity, and can be used for detecting the sheep SRA protein.

The present disclosure is directed to a method of detecting a helminth a antigen in a sample comprising (a) contacting a sample with human antibodies and fragments thereof, comprising clone-paired heavy and light chain CDR sequences, and (b) detecting a helminth antigen in said sample by binding of said human antibody or antibody fragment to a helminth antigen in said sample.

A preparation method for a transferrin receptor-targeting glycoside hydrolase complex, and a use thereof. The transferrin receptor-targeting glycoside hydrolase complex is formed by complexing a glycoside hydrolase with a human ferritin heavy chain. The present invention fuses a molecular glue peptide pair (ST-SC) with glycoside hydrolases (FpGalNAc and FpGal) and hFn, respectively, to prepare a glycoside hydrolase and hFn containing molecular glue peptides, and couples the glycoside hydrolase and hFn together to prepare a transferrin receptor 1-targeting glycoside hydrolase complex. The complex significantly improves the activity of the glycoside hydrolase cleaving a type A antigen. The glycoside hydrolase complex can convert a type-A organ into a type-O organ without requiring the use of dextran, overcoming a series of side effects of existing methods which are caused by the use of dextran, can effectively alleviate the problem of supply shortage in clinical organ transplantation, and has wide application prospects.

This disclosure relates to immunogenic compositions comprising Borrelia cell surface protein A (OspA) antigen or RNA polynucleotide encoding the OspA antigen, and an adjuvant. In some embodiments, the immunogenic compositions are suitable for stimulating an immune response to Borrelia in a subject. This disclosure also relates to kits of immunogenic compositions, their use, and methods of using them.

The present application relates to a kind of reagent and kit for rapid detection of blood group and purposes thereof, belong to blood group detection field.The reagent includes anti-A antigen nanobody, anti-B antigen nanobody and anti-RhD antigen nanobody.Based on the blood group detection reagent card prepared using the nanobody, blood group agglutination reaction is used to detect blood group in the sample to be measured, and the detection result can be observed in only 30s, and has the advantages of high sensitivity, low cost, storage resistance.

The present invention relates to cancer vaccines and methods of treatment using the same. Disclosed is a vaccine composition, the present invention relates to a composition comprising one or more nucleic acids encoding one or more amino acid sequences selected from the group consisting of a tyrosinase, a tyrosinase-associated protein 1, a tyrosinase-associated protein 2, a melanoma-associated antigen 4 protein, a growth hormone releasing hormone, a MART-1 / melan-A antigen, a cancerous testis antigen NY-ESO-1, a cancerous testis antigen NY-ESO-2, the amino acid sequences of the antigen, the Vilms tumor 1 and the human telomerase reverse transcriptase are preferentially expressed in the melanoma. The vaccine compositions may further comprise nucleic acids encoding one or more other antigens, including prostate-specific antigens. Also disclosed are methods of preventing or treating cancer in a subject in need thereof, comprising administering to the subject a vaccine composition comprising a specific amount of cancer antigens to treat or prevent a specific cancer.